Targeted based therapy in nodal T-cell lymphomas.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
21
09
2020
accepted:
08
02
2021
revised:
19
01
2021
pubmed:
6
3
2021
medline:
1
5
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
T-cell lymphomas (TCL) are a group of biologically and clinically heterogenous neoplasms derived from mature T lymphocytes. Recent findings in biology have advanced the classification of these neoplasms; however, clinical investigations based on biologic features have yet to be designed. Two biomarker-driven treatments for TCL are promising: brentuximab vedotin (BV) in combination with chemotherapy or as monotherapy is the standard treatment for newly diagnosed CD30-positive TCL and relapsed/refractory anaplastic large cell lymphoma (ALCL), while ALK inhibitors have induced responses in ALK+ ALCLs. Common genetic alterations in TCL, such as aberrations in PI3K/mTOR, JAK/STAT, and epigenetic regulators are also targetable by pathway inhibitors and HDAC/DNMT inhibitors; however, responses to these treatments as monotherapy are neither satisfactory nor durable, even in patients pre-stratified by several biomarkers. Additional work is needed to extend biology/biomarker-driven treatment in these neoplasms. As T-cell lymphomagenesis is multistep and multifactorial, trials are ongoing to evaluate combination treatments. The focus of this article is to summarize the status and the current role of targeted-based therapy in nodal TCL.
Identifiants
pubmed: 33664464
doi: 10.1038/s41375-021-01191-8
pii: 10.1038/s41375-021-01191-8
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
956-967Références
Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-Cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016;34:963–71.
pubmed: 26962200
pmcid: 5070555
doi: 10.1200/JCO.2015.63.5540
Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45.
pubmed: 24245986
doi: 10.1111/bjh.12659
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–76.
pubmed: 16150940
pmcid: 1895348
doi: 10.1182/blood-2005-06-2508
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA: a cancer J clinicians. 2016;66:443–59.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
pubmed: 26980727
pmcid: 4874220
doi: 10.1182/blood-2016-01-643569
Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.
pubmed: 18626005
doi: 10.1200/JCO.2008.16.4558
Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103:1191–97.
pubmed: 29599200
pmcid: 6029527
doi: 10.3324/haematol.2017.186577
Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176:750–8.
pubmed: 27983760
doi: 10.1111/bjh.14477
Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–7.
pubmed: 25006130
doi: 10.1182/blood-2014-04-573089
Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6.
pubmed: 23610113
doi: 10.1200/JCO.2012.44.7524
O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–9.
pubmed: 21245435
pmcid: 3083873
doi: 10.1200/JCO.2010.29.9024
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–6.
pubmed: 22271479
doi: 10.1200/JCO.2011.37.4223
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–6.
pubmed: 22614995
doi: 10.1200/JCO.2011.38.0402
O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492–9.
pubmed: 26101246
pmcid: 5087312
doi: 10.1200/JCO.2014.59.2782
Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ. Novel insights into the pathogenesis of T-cell lymphomas. Blood. 2018;131:2320–30.
pubmed: 29666117
doi: 10.1182/blood-2017-11-764357
Jacobsen ED, Weinstock DM. Challenges and implications of genomics for T-cell lymphomas. Hematol Am Soc Hematol Educ Program. 2018;201:63–68.
doi: 10.1182/asheducation-2018.1.63
Sandell RF, Boddicker RL, Feldman AL. Genetic landscape and classification of peripheral T cell lymphomas. Curr Oncol Rep. 2017;19:28.
pubmed: 28303495
pmcid: 5517131
doi: 10.1007/s11912-017-0582-9
Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133:1664–76.
pubmed: 30782609
pmcid: 6460420
doi: 10.1182/blood-2018-09-872549
Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123:3007–15.
pubmed: 24497534
pmcid: 4014843
doi: 10.1182/blood-2013-12-544809
Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123:2915–23.
pubmed: 24632715
pmcid: 4014836
doi: 10.1182/blood-2013-11-536359
Ma H, O’Connor OA, Marchi E. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. Expert Rev Hematol. 2019;12:137–46.
pubmed: 30782038
doi: 10.1080/17474086.2019.1583102
Fukumoto K, Nguyen TB, Chiba S, Sakata-Yanagimoto M. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. Cancer Sci. 2018;109:490–6.
pubmed: 28889481
doi: 10.1111/cas.13393
Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, et al. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019;133:566–75.
pubmed: 30498064
pmcid: 6367646
doi: 10.1182/blood-2018-07-865527
Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9:2024.
pubmed: 29789628
pmcid: 5964252
doi: 10.1038/s41467-018-04356-9
Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, et al. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood. 2015;125:124–32.
pubmed: 25359993
doi: 10.1182/blood-2014-08-594507
Boddicker RL, Kip NS, Xing X, Zeng Y, Yang ZZ, Lee JH, et al. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-kappaB positive feedback loop in peripheral T-cell lymphoma. Blood. 2015;125:3118–27.
pubmed: 25833963
pmcid: 4432006
doi: 10.1182/blood-2014-05-578575
Buchan SL, Al-Shamkhani A. Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-kappaB signaling. PLoS One. 2012;7:e45244.
pubmed: 23028875
pmcid: 3445475
doi: 10.1371/journal.pone.0045244
Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281:10540–7.
pubmed: 16484228
doi: 10.1074/jbc.M510026200
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709–17.
pubmed: 28974506
pmcid: 5746164
doi: 10.1182/blood-2017-05-780049
Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, et al. The survival outcome of the patients with relapsed/refractory anaplastic large-cell lymphoma. Blood. 2015;126:2738.
doi: 10.1182/blood.V126.23.2738.2738
Chihara D, Wong S, Feldman T, Fanale MA, Sanchez L, Connors JM, et al. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. Hematological Oncol. 2019;37:35–38.
doi: 10.1002/hon.2560
Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124:2983–6.
pubmed: 25224410
doi: 10.1182/blood-2014-07-584953
Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98:e81–82.
pubmed: 23716537
pmcid: 3729886
doi: 10.3324/haematol.2013.084913
Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood. 2011;117:3402–8.
pubmed: 21270441
doi: 10.1182/blood-2010-09-310342
Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472–9.
pubmed: 16636342
doi: 10.1200/JCO.2005.03.6327
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single agent brentuximab vedotin. Blood. 2014;123:3095–4100.
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30 expressing peripheral T-cell lymphomas. Blood. 2018;131:2120–4.
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32:3137–43.
pubmed: 25135998
pmcid: 4171358
doi: 10.1200/JCO.2013.54.2456
Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–40.
pubmed: 30522922
doi: 10.1016/S0140-6736(18)32984-2
Voorhees T, Ghosh N, Dotti G, Savoldo B, Grover N, Beaven A. Long term remission in multiply relapsed enteropathy associated T-cell lymphoma type 1 following CD30 redirected chimeric antigen receptor T-cell therapy. La Jolla, CA: T-cell Lymphoma Forum; 2020.
Hill LC, Rouce RH, Smith TS, Yang L, Srinivasan M, Zhang H, et al. Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies. Blood. 2019;134:199.
doi: 10.1182/blood-2019-129559
Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46:166–70.
pubmed: 24413734
pmcid: 3963408
doi: 10.1038/ng.2873
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.
pubmed: 24456586
pmcid: 4016573
doi: 10.1186/1756-8722-7-11
Ghione P, Ozkaya N, Faruque P, Mehta-Shah N, Lunning MA, Ruan J, et al. Romidepsin activity in T follicular helper(TFH)-phenotype PTCL versus non TFH treated on the same clinical trials. J Clin Oncol. 2018;36:7509.
doi: 10.1200/JCO.2018.36.15_suppl.7509
Sawas A, Ma H, Shustov A, Hsu PL, Bhat G, Acosta M, et al. Belinostat induces high overall response rate (ORR) in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). Blood. 2019;134:4050.
doi: 10.1182/blood-2019-127155
Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132:2305–9.
pubmed: 30279227
doi: 10.1182/blood-2018-04-840538
Marchi E, Zullo KM, Amengual JE, Kalac M, Bongero D, McIntosh CM, et al. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol. 2015;171:215–26.
pubmed: 26194163
doi: 10.1111/bjh.13566
O’Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with Ptcl: A Multicenter Phase I Study. Blood. 2019;134:1395–405.
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A Multicenter Phase 2 Study. Blood. 2020. Epub ahead of print.
Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Rahim R, et al. Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL). Blood. 2020;136:33–34.
doi: 10.1182/blood-2020-136023
Johnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, et al. Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the Bel-CHOP phase 1 trial. Blood. 2015;126:253.
doi: 10.1182/blood.V126.23.253.253
Dupuis J, Morschhauser F, Ghesquieres H, Tilly H, Casasnovas O, Thieblemont C, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. Lancet Haematol. 2015;2:e160–5.
pubmed: 26687958
doi: 10.1016/S2352-3026(15)00023-X
Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, et al. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2013;162:138–41.
pubmed: 23590726
doi: 10.1111/bjh.12326
Bachy E, Camus V, Thieblemont C, Casasnovas RO, Ysebaert L, Damaj GL, et al. Final analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma. Blood. 2020;136:32–33.
doi: 10.1182/blood-2020-134440
Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920–4.
pubmed: 15070664
doi: 10.1182/blood-2003-10-3389
Wulf GG, Altmann B, Ziepert M, D’Amore F, Held G, Greil R, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia. 2020;35:143–55.
Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma. 2013;54:1373–9.
pubmed: 23278639
doi: 10.3109/10428194.2012.742521
Foss F, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith M, et al. Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial. Blood. 2007;110:3449.
doi: 10.1182/blood.V110.11.3449.3449
Collins GP, Horwitz SM, Davies A, Karnad A, Samaniego F, Spira AI, et al. Adct-301 (Camidanlumab Tesirine), a novel pyrrolobenzodiazepine-based CD25-targeting antibody drug conjugate, in a Phase 1 study of relapsed/refractory non-hodgkin lymphoma shows activity in T-cell lymphoma. Blood. 2018;132:1658.
doi: 10.1182/blood-2018-99-115986
Marafioti T, Paterson JC, Ballabio E, Chott A, Natkunam Y, Rodriguez-Justo M, et al. The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica. 2010;95:432–9.
pubmed: 20207847
pmcid: 2833073
doi: 10.3324/haematol.2009.010991
Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, et al. A phase I study of anti-ICOS antibody MEDI-570 for relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL) (NCI-9930). Blood. 2020;136:5–6.
doi: 10.1182/blood-2020-136465
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–4.
pubmed: 8122112
doi: 10.1126/science.8122112
Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018;13:e0191461.
pubmed: 29538376
pmcid: 5851529
doi: 10.1371/journal.pone.0191461
Bossi E, Aroldi A, Brioschi FA, Steidl C, Baretta S, Renso R, et al. Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. Am J Hematol. 2020;12:E319–21.
Nagai H, Fukano R, Sekimizu M, Kada A, Akiko MS, Asada R, et al. Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. Nagoya J Med Sci. 2017;79:407–13.
pubmed: 28878445
pmcid: 5577026
Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106:djt378.
pubmed: 24491302
doi: 10.1093/jnci/djt378
Mosse YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A Children’s Oncology Group Study. J Clin Oncol. 2017;35:3215–21.
pubmed: 28787259
pmcid: 5617123
doi: 10.1200/JCO.2017.73.4830
Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472–80.
pubmed: 23598171
pmcid: 3730818
doi: 10.1016/S1470-2045(13)70095-0
Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib. N. Engl J Med. 2016;374:95–96.
pubmed: 26736010
doi: 10.1056/NEJMc1511045
Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl J Med. 2013;368:2385–94.
pubmed: 23724913
doi: 10.1056/NEJMoa1214886
Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428–33.
pubmed: 28280247
pmcid: 6286077
doi: 10.1126/science.aaf1292
Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20:323–42.
pubmed: 32249838
doi: 10.1038/s41568-020-0247-0
Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, et al. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood. 2018;132:1386–98.
pubmed: 30093402
pmcid: 6161771
doi: 10.1182/blood-2018-03-838524
Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131:888–98.
pubmed: 29233821
pmcid: 5824337
doi: 10.1182/blood-2017-08-802470
Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169–78.
pubmed: 28633365
pmcid: 5834070
doi: 10.1093/annonc/mdx289
Pro B, Brammer JE, Casulo C, Jacobsen E, Mead M, Mehta-Shah N, et al. Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 primo trial: dose optimization efficacy update and expansion phase initial results. Blood. 2020;136:38–39.
doi: 10.1182/blood-2020-140412
Iyer SP, Haverkos BM, Zain J, Ramchandren R, Lechowicz MJ, Devata S, et al. Final results of phase 1/1b Study of Tenalisib, dual PI3K δ/γ inhibitor in patients with relapsed/refractory T-cell lymphoma. Blood. 2019;134:2831.
doi: 10.1182/blood-2019-123954
Moskowitz AJ, Ghione P, Jacobsen ED, Ruan J, Schatz JH, Noor S, et al. Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma. Blood. 2019;134:4019.
doi: 10.1182/blood-2019-125017
Horwitz SM, Feldman TA, Hess BT, Khodadoust MS, Kim YH, Munoz J, et al. A phase 2 study of the dual SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood. 2019;134:466.
doi: 10.1182/blood-2019-123986
Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126:328–35.
pubmed: 25921059
pmcid: 4504947
doi: 10.1182/blood-2015-02-629543
Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011;118:4882–9.
pubmed: 21725056
pmcid: 3208296
doi: 10.1182/blood-2011-02-334904
Witzig T, Sokol L, Jacobsen E, Advani AS, Mondejar R, Piris M, et al. Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma. Hematological Oncol. 2017;35:9–21.
Witzig TE, Sokol L, Foss FM, Kim WS, Jacobsen E, De La Cruz MDF, et al. Proof of concept for tipifarnib in relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-cell lymphoma (PTCL): preliminary results from an open-label, phase 2 study. Blood. 2019;134:468.
doi: 10.1182/blood-2019-128513
Barta SK, Zain J, MacFarlane AWT, Smith SM, Ruan J, Fung HC, et al. Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19:356–64 e353.
pubmed: 31029646
pmcid: 7433797
doi: 10.1016/j.clml.2019.03.022
Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N. Engl J Med. 2018;378:1947–8.
pubmed: 29768155
doi: 10.1056/NEJMc1803181
Rauch DA, Conlon KC, Janakiram M, Brammer JE, Harding JC, Ye BH, et al. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. Blood. 2019;134:1406–14.
pubmed: 31467059
pmcid: 6839957
doi: 10.1182/blood.2019002038
Wartewig T, Kurgyis Z, Keppler S, Pechloff K, Hameister E, Ollinger R, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552:121–5.
pubmed: 29143824
pmcid: 5821214
doi: 10.1038/nature24649
Bennani NN, Pederson LD, Atherton P, Micallef I, Colgan JP, Thanarajasingam G, et al. A phase II study of nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma. Blood. 2019;134:467.
doi: 10.1182/blood-2019-126194
Iyer SP, Xu J, Becnel MR, Nair R, Steiner R, Feng L, et al. A phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL). Blood. 2020;136:40–41.
doi: 10.1182/blood-2020-143252